Please use this identifier to cite or link to this item:
http://hdl.handle.net/1942/36311
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | EVENS, Lize | - |
dc.contributor.author | HEEREN, Ellen | - |
dc.contributor.author | RUMMENS, Jean-Luc | - |
dc.contributor.author | BRONCKAERS, Annelies | - |
dc.contributor.author | HENDRIKX, Marc | - |
dc.contributor.author | DELUYKER, Dorien | - |
dc.contributor.author | BITO, Virginie | - |
dc.date.accessioned | 2021-12-21T14:20:32Z | - |
dc.date.available | 2021-12-21T14:20:32Z | - |
dc.date.issued | 2021 | - |
dc.date.submitted | 2021-08-23T13:25:04Z | - |
dc.identifier.citation | Journal of clinical medicine, 10 (13) (Art N° 2964) | - |
dc.identifier.uri | http://hdl.handle.net/1942/36311 | - |
dc.description.abstract | Background: During myocardial infarction (MI), billions of cardiomyocytes are lost. The optimal therapy should effectively replace damaged cardiomyocytes, possibly with stem cells able to engraft and differentiate into adult functional cardiomyocytes. As such, cardiac atrial appendage stem cells (CASCs) are suitable candidates. However, the presence of elevated levels of advanced glycation end products (AGEs) in cardiac regions where CASCs are transplanted may affect their regenerative potential. In this study, we examine whether and how AGEs alter CASCs properties in vitro. Methods and Results: CASCs in culture were exposed to ranging AGEs concentrations (50 mu g/mL to 400 mu g/mL). CASCs survival, proliferation, and migration capacity were significantly decreased after 72 h of AGEs exposure. Apoptosis significantly increased with rising AGEs concentration. The harmful effects of these AGEs were partially blunted by pre-incubation with a receptor for AGEs (RAGE) inhibitor (25 mu M FPS-ZM1), indicating the involvement of RAGE in the observed negative effects. Conclusion: AGEs have a time- and concentration-dependent negative effect on CASCs survival, proliferation, migration, and apoptosis in vitro, partially mediated through RAGE activation. Whether anti-AGEs therapies are an effective treatment in the setting of stem cell therapy after MI warrants further examination. | - |
dc.description.sponsorship | This work was supported by a Bijzonder onderzoeksfonds (BOF) grant from Hasselt University, grant number: 16NI05BOF. The graphical abstract was created using images from Servier Medical Art Commons Attribution 3.0 Unported License (http://smart.servier.com (accessed on 29 June 2021)). Servier Medical Art by Servier is licensed under a Creative Commons Attribution 3.0 Unported License. | - |
dc.language.iso | en | - |
dc.publisher | MDPI | - |
dc.rights | 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https:// creativecommons.org/licenses/by/4.0/). | - |
dc.subject.other | stem cells | - |
dc.subject.other | aldehyde dehydrogenase | - |
dc.subject.other | CASCs | - |
dc.subject.other | glycated proteins | - |
dc.subject.other | advanced glycation end products | - |
dc.subject.other | proliferation | - |
dc.subject.other | apoptosis | - |
dc.subject.other | migration | - |
dc.subject.other | RAGE inhibition | - |
dc.title | Advanced Glycation End Products Impair Cardiac Atrial Appendage Stem Cells Properties | - |
dc.type | Journal Contribution | - |
dc.identifier.issue | 13 | - |
dc.identifier.volume | 10 | - |
local.bibliographicCitation.jcat | A1 | - |
local.publisher.place | ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND | - |
local.type.refereed | Refereed | - |
local.type.specified | Article | - |
local.bibliographicCitation.artnr | 2964 | - |
dc.identifier.doi | 10.3390/jcm10132964 | - |
dc.identifier.pmid | 34279448 | - |
dc.identifier.isi | 000671401400001 | - |
local.provider.type | Web of Science | - |
local.uhasselt.international | no | - |
item.validation | ecoom 2022 | - |
item.contributor | EVENS, Lize | - |
item.contributor | HEEREN, Ellen | - |
item.contributor | RUMMENS, Jean-Luc | - |
item.contributor | BRONCKAERS, Annelies | - |
item.contributor | HENDRIKX, Marc | - |
item.contributor | DELUYKER, Dorien | - |
item.contributor | BITO, Virginie | - |
item.accessRights | Open Access | - |
item.fullcitation | EVENS, Lize; HEEREN, Ellen; RUMMENS, Jean-Luc; BRONCKAERS, Annelies; HENDRIKX, Marc; DELUYKER, Dorien & BITO, Virginie (2021) Advanced Glycation End Products Impair Cardiac Atrial Appendage Stem Cells Properties. In: Journal of clinical medicine, 10 (13) (Art N° 2964). | - |
item.fulltext | With Fulltext | - |
crisitem.journal.eissn | 2077-0383 | - |
Appears in Collections: | Research publications |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
Advanced Glycation End Products Impair Cardiac Atrial Appendage Stem Cells Properties.pdf | Published version | 2.84 MB | Adobe PDF | View/Open |
WEB OF SCIENCETM
Citations
1
checked on Apr 30, 2024
Page view(s)
38
checked on Jun 14, 2022
Download(s)
12
checked on Jun 14, 2022
Google ScholarTM
Check
Altmetric
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.